Equasens S. A. (EQS)
Euronext Paris · France · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 28.65 |
|---|---|
| 52-week range | 27.45 – 43.51 |
| Return, 1 month / 3 months | −7.4% / −14.3% |
| Return, 1 year / 3 years | −26.1% / −51.5% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 33.6% |
| Worst drawdown (1 year) | -34.2% |
| Average daily value traded | 0.74M EUR |
| Dividend yield | 4.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Equasens is a French software company that supplies information technology for pharmacies and other healthcare professionals. Its main business is pharmacy management software, which helps pharmacists run dispensing, stock and patient records, alongside related hardware and services. The company also provides software for medical laboratories, care homes and other health providers. It is based in France and serves customers mainly in its home market and elsewhere in Europe.
Equasens S. A. trades under the code EQS on the Euronext Paris in France, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Equasens S. A. (EQS) trades on the Euronext Paris in France. It last closed at EUR 28.65 on 19 October 2026.
Its price-based Market X-Ray is 48 out of 100 (a weak price profile), ranking 358 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 26.1% and over the last three months it fell 14.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 33 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -17.4% | ||
| From 52-week high | -33.6% | ||
| Momentum | 30 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -14.4% | ||
| 6-month return | -26.3% | ||
| 12-month return, skipping the last month | -20.2% | ||
| Risk (lower is better) | 57 · Fair | Typical risk for this exchange. | |
| Volatility (1 year) | 33.6% | ||
| Worst drawdown (1 year) | -34.2% | ||
| Liquidity | 77 · Strong | Trades actively. | |
| Average daily value traded | 0.74M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 62 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.9% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −1.0% |
|---|---|
| 1 month | −7.4% |
| 3 months | −14.3% |
| 6 months | −26.3% |
| 1 year | −26.1% |
| 3 years | −51.5% |
| 5 years | −65.2% |
Signals
| 50-day / 200-day average | 31.37 / 34.67 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.96 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 Jul 2026 | EUR 1.4000 |
| 2 Jul 2025 | EUR 1.2500 |
| 2 Jul 2024 | EUR 1.2500 |
| 3 Jul 2023 | EUR 1.1500 |
| 30 Jun 2022 | EUR 1.0500 |
| 1 Jul 2021 | EUR 0.9500 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.